1045709-74-7

Basic information

• Product Name: 2-{3-[1-p-methoxybenzylcarboxylate-(5-aminopentyl)]ureido}-di-p-methoxybenzyl pentanedioate
• Synonyms: 2-{3-[1-p-methoxybenzylcarboxylate-(5-aminopentyl)]ureido}-di-p-methoxybenzyl pentanedioate
• CAS NO: 1045709-74-7
• Molecular Weight: 679.767
• Mol File: 1045709-74-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-{3-[1-p-methoxybenzylcarboxylate-(5-aminopentyl)]ureido}-di-p-methoxybenzyl pentanedioate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-{3-[1-p-methoxybenzylcarboxylate-(5-aminopentyl)]ureido}-di-p-methoxybenzyl pentanedioate(1045709-74-7)
• EPA Substance Registry System: 2-{3-[1-p-methoxybenzylcarboxylate-(5-aminopentyl)]ureido}-di-p-methoxybenzyl pentanedioate(1045709-74-7)

Safety Data

• Hazardous Substances Data: 1045709-74-7(Hazardous Substances Data)

Upstream product

• 1045709-90-7 (S)-5-(3-((S)-1,5-bis((4-methoxybenzyl)oxy)-1,5-dioxopentan-2-yl)ureido)-6-((4-methoxybenzyl)oxy)-6-oxohexan-1-aminium tosylate 

Downstream Products

• 1045709-75-8 2-{3-[5-[7-(2,5-dioxopyrrolidin-1-yloxycarbonyl)heptanoylamino]-1-(4-methoxybenzyloxycarbonyl)pentyl]ureido}pentanedioic acid bis-(4-methoxybenzyl) ester 
• 1207181-34-7 C₄₃H₄₈⁽¹²⁵⁾IN₃O₁₁ 
• 1207181-33-6 C₄₂H₄₇⁽¹²⁵⁾IN₄O₁₁ 
• 1093733-07-3 2-[3-[5-(4-iodo-benzoylamino)-1-(4-methoxy-benzyloxycarbonyl)-pentyl]-ureido]-pentanedioic acid bis-(4-methoxybenzyl)ester 
• 1093733-09-5 2-[3-[5-(4-fluoro-benzoylamino)-1-(4-methoxy-benzyloxycarbonyl)-pentyl]-ureido]-pentanedioic acid bis-(4-methoxy-benzyl)ester 

Relevant articles and documents

Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA)

The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. We prepared seven 99mTc/Re-labeled compounds by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor (lys-NHCONH-glu) with or without a variable length linker moiety. Ki values ranged from 0.17 to 199 nM. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors. PC3-PIP cells are derived from PC3 that have been transduced with the gene for PSMA. Despite demonstrating nearly the lowest PSMA inhibitory potency of this series, [99mTc(CO) 3(L1)]+ (L1 = (2-pyridylmethyl)2N(CH 2)4CH(CO2H)-NHCO-(CH2) 6CO-NH-lys-NHCONH-glu) showed the highest, most selective PIP tumor uptake, at 7.9 ± 4.0% injected dose per gram of tissue at 30 min postinjection. Radioactivity cleared from nontarget tissues to produce a PIP to flu (PSMA-PC3) ratio of 44:1 at 120 min postinjection. PSMA can accommodate the steric requirements of 99mTc/Re complexes within PSMA inhibitors, the best results achieved with a linker moiety between the ε amine of the urea lysine and the chelator.